📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,076
All-time analysed
43,619
Positive
6,746
Negative
92,864
Neutral
8,779
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
848 announcements match the current filters (relevance ≥ 5).
Ambica Agarbathies to raise ₹2.12 Cr via preferential issue of 8.48 lakh shares to promoters
Ambica Agarbathies & Aroma Industries Limited has called an Extraordinary General Meeting (EGM) on June 30, 2026, to approve the issuance of 8,48,600 equity shares on a preferential basis. The shares will be allotted to four members of the Promoter Group at a price of ₹25 per share (including a ₹15 premium), totaling approximately ₹2.12 crore. This capital infusion by the promoters indicates a commitment to the company's financial health and future growth. The relevant date for the purpose of determining the issue price has been set as May 29, 2026.
Key Highlights
Proposed issuance of 8,48,600 equity shares of face value ₹10 each on a preferential basis.
Issue price fixed at ₹25 per share, aggregating to a total fundraise of ₹2,12,15,000.
Allotment is restricted to four specific individuals within the Promoter Group.
The EGM is scheduled for June 30, 2026, at the company's registered office in Andhra Pradesh.
Remote e-voting period is set from June 27 to June 29, 2026, with a cut-off date of June 23.
👀 What to Watch
Investors should view the promoter capital infusion as a sign of confidence in the company's prospects, though they should also monitor the resulting equity dilution and the specific end-use of the funds.
IFB Industries to Host Q4 and FY26 Earnings Conference Call on June 10, 2026
IFB Industries Limited has scheduled a conference call for June 10, 2026, at 4:00 PM IST to discuss its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The call is being organized by Nirmal Bang Institutional Equities and will feature top management including the Chairman, MD & CEO, and CFOs of various divisions. This meeting provides an opportunity for analysts and institutional investors to gain insights into the company's performance across its Home Appliances and Engineering segments.
Key Highlights
Conference call scheduled for June 10, 2026, at 16:00 IST to discuss Q4 and FY26 results.
Senior management representation includes Chairman Bikramjit Nag and MD & CEO Sandeep Joseph Abraham.
The discussion will cover both Standalone and Consolidated audited financial results for the period ended March 31, 2026.
Universal dial-in numbers provided are +91 22 6280 1304 and +91 22 7115 8205.
👀 What to Watch
Investors should attend or review the transcript of the call to understand management's outlook on the Home Appliances Division (HAD) and the Engineering business's growth trajectory. Key metrics to watch include margin recovery and demand trends in the consumer durables sector.
SBIN Appoints Ratna Teja Dinakara Akella as Deputy Managing Director & Group Chief Risk Officer
State Bank of India (SBIN) has announced a senior management update effective June 5, 2026. Shri Ratna Teja Dinakara Akella, who serves as a Deputy Managing Director, has been designated as the new Group Chief Risk Officer (GCRO). This appointment is a key regulatory disclosure under SEBI (LODR) Regulations, 2015, ensuring continuity in the bank's risk management framework. As the GCRO of India's largest lender, Akella will be responsible for overseeing the group's entire risk profile.
Key Highlights
Shri Ratna Teja Dinakara Akella appointed as Group Chief Risk Officer (GCRO).
The appointee currently holds the position of Deputy Managing Director within SBIN.
The disclosure was made on June 5, 2026, under Regulation 30 of SEBI (LODR) Regulations.
The role is critical for managing the risk framework of India's largest public sector bank.
👀 What to Watch
This is a routine senior management appointment; investors should maintain their current positions while monitoring for any future changes in the bank's risk management or provisioning policies.
IFB Industries to Host Q4 & FY26 Earnings Call on June 10, 2026, at 4:00 PM IST
IFB Industries Limited has scheduled a conference call on June 10, 2026, at 4:00 PM IST to discuss its audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026. The call is being hosted by Nirmal Bang Institutional Equities and will feature top management including the Chairman, MD & CEO, and CFO. This session provides an opportunity for analysts and investors to gain insights into the company's performance across its Home Appliances and Engineering divisions.
Key Highlights
Conference call scheduled for June 10, 2026, at 04:00 P.M. IST to discuss Q4 and FY26 results.
Top management participation including Chairman Bikramjit Nag and MD & CEO Sandeep Joseph Abraham.
Discussion will cover both Standalone and Consolidated audited financial results for the period ending March 31, 2026.
Dial-in details provided with universal numbers +91 22 6280 1304 and +91 22 7115 8205.
👀 What to Watch
Investors should attend the call to understand management's guidance on margin recovery in the Home Appliances Division and growth prospects for the Engineering business in FY27.
Tasty Bite Seeks Approval for ₹5,000 Million+ Related Party Transactions and Director Pay Revision
Tasty Bite Eatables Limited has issued a Postal Ballot notice to seek shareholder approval for significant Related Party Transactions (RPTs) for the Financial Year 2026-27. The company is proposing a transaction limit of ₹3,000 million with its holding company, Preferred Brands International, and ₹2,000 million with Mars Food UK Limited. Additionally, the company is seeking post-facto approval for RPTs conducted in FY 2025-26 and a revision in the remuneration of Independent Director Rahul Bhatnagar.
Key Highlights
Proposed RPT limit of ₹3,000 million with Preferred Brands International Inc. for sale of goods and services in FY 2026-27.
Proposed RPT limit of ₹2,000 million with Mars Food UK Limited for FY 2026-27.
Seeking post-facto approval for material related party transactions already entered with Mars Food UK Limited for FY 2025-26.
Proposed revision in remuneration and commission for Independent Director Mr. Rahul Bhatnagar.
E-voting period for shareholders starts on June 4, 2026, and concludes on July 3, 2026.
👀 What to Watch
Investors should review the explanatory statement to ensure RPTs are conducted at arm's length and monitor the reasons for seeking post-facto approval for previous transactions.
Birla Corp Promoters Confirm Zero Pledged Shares for FY26; Total Promoter Stake at 62.90%
Vindhya Telelinks Limited, on behalf of the promoter group, has filed a declaration under Regulation 31(4) of SEBI Takeover Regulations for the financial year ended March 31, 2026. The filing confirms that the promoters have not created any encumbrance, directly or indirectly, on their equity shares in Birla Corporation Limited. The total promoter group holding stands at 48,434,191 shares, representing 62.90% of the company's total equity. This annual disclosure ensures transparency regarding the unpledged status of the majority shareholding.
Key Highlights
Promoter group confirms zero encumbrance on their 62.90% stake in Birla Corporation for FY 2025-26.
Total promoter shareholding comprises 48,434,191 equity shares held across 23 entities.
Major promoter entities include Hindustan Medical Institution (9.30%), Vindhya Telelinks (8.29%), and August Agents (7.81%).
The declaration covers the main promoter and its three wholly-owned subsidiaries: August Agents, Insilco Agents, and Laneseda Agents.
Seven additional promoter group entities were identified as having nil shareholding but are included in the compliance scope.
👀 What to Watch
Investors should view the absence of pledged shares as a sign of promoter financial stability and confidence. No immediate action is required, but this confirms a low-risk ownership structure regarding margin-call threats.
Rubicon Research Q4 FY26 PAT Jumps 111% YoY; Revenue Up 44% to INR 5,139 Million
Rubicon Research reported a stellar Q4 FY26 with revenue growing 44% YoY to INR 5,139 million and PAT surging 111% to INR 768 million. The full-year FY26 revenue reached INR 17,540 million, driven by a robust specialty portfolio and 12 new product approvals. While gross margins saw a slight dip due to increased reliance on outsourced manufacturing to meet high demand, EBITDA margins remained healthy at 23.1%. The company has a strong pipeline with 24 products under FDA review and expects the Pithampur facility to ramp up by Q1 CY2027.
Key Highlights
Q4 FY26 revenue grew 44% YoY to INR 5,139 million; PAT increased 111% to INR 768 million.
Full-year FY26 PAT stood at INR 2,467 million, representing a significant 84% growth over the previous year.
R&D productivity reached 5.9x for the FY26-FY23 period, with 24 products currently under US FDA review.
The Board recommended a 150% dividend (INR 1.5 per share) with a 10% payout ratio.
Specialty portfolio contributed 33% to the total gross profit for the quarter, reflecting a shift toward high-value products.
👀 What to Watch
Investors should monitor the Pithampur facility's FDA inspection and commercialization in early 2027, as it is key to improving gross margins by reducing outsourcing. The strong R&D productivity and robust pipeline suggest continued growth momentum, making it a strong 'Hold' or 'Accumulate' on dips.
BIL Vyapar 12th CoC Meeting: FY26 Income at ₹1.73 Cr; Fraud Suspected in ₹1.5 Cr Land Sale
BIL Vyapar Limited, currently under the Corporate Insolvency Resolution Process (CIRP), reported a standalone income of ₹1.73 crore for FY26, primarily derived from interest on fixed deposits. The Resolution Professional (RP) has identified a potential fraudulent transaction involving the company's Sirohi land, valued at ₹1.5 crore in the books, which appears to have been sold to 45 different parties without authorization. Furthermore, the company's US-based subsidiary, Global Composite Holdings Inc., was dissolved on May 21, 2026, without prior notice to the RP. The Committee of Creditors, led by Punjab National Bank with an 80.08% voting share, is currently vetting resolution plans from prospective applicants.
Key Highlights
Reported standalone income of ₹1.73 crore for FY26 with a net loss of ₹3.34 lakhs; company has no current operations.
RP to file an avoidance application for fraudulent transactions regarding Sirohi land (book value ₹1.5 crore) sold to 45 parties.
Global Composite Holdings Inc. (USA subsidiary) dissolved on May 21, 2026, without intimation to the Resolution Professional.
Punjab National Bank dominates the Committee of Creditors with a total voting share of 80.08%.
Resolution plans from prospective applicants are currently under technical vetting and negotiation.
👀 What to Watch
Investors should exercise extreme caution as the company is in insolvency with no operations and significant legal disputes regarding asset stripping. The final recovery for shareholders is highly uncertain and depends on the NCLT's approval of a resolution plan.
Concord Biotech Secures USFDA Approval for Mycophenolate Mofetil; US Market Size $30 Million
Concord Biotech Limited has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. This immunosuppressant is used to prevent organ rejection in kidney, heart, or liver transplant patients. The U.S. market for this specific product is estimated at approximately US$ 30 million. This approval is a key step in the company's strategy to expand its presence and product offerings in the U.S. and international markets.
Key Highlights
Received USFDA approval for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.
The estimated U.S. market size for this product is approximately US$ 30 million.
Indicated for prophylaxis of organ rejection in adult and pediatric transplant recipients.
Strengthens the company's position in the U.S. market and supports long-term growth strategy.
Approval follows Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👀 What to Watch
Investors should view this as a positive development that adds a new revenue stream in the U.S. market. Monitor the company's execution in capturing market share within this $30 million segment.
MobiKwik to Transfer LSP Business to Subsidiary and Amend MoA for Payment Aggregator Services
One MobiKwik Systems Limited is seeking shareholder approval to transfer its Lending Services Provider (LSP) business to its wholly-owned subsidiary, MobiKwik Distribution Services Private Limited (MDSPL), via a slump sale at book value. Additionally, the company proposes to amend its Memorandum of Association to formally include payment aggregator and gateway services, aligning with RBI regulatory requirements. The e-voting process for these special resolutions will take place between June 03, 2026, and July 02, 2026.
Key Highlights
Proposed slump sale of the Lending Services Provider (LSP) business to wholly-owned subsidiary MDSPL at book value.
Amendment of the Memorandum of Association to include sub-clause (10) for payment aggregator, gateway, and intermediary services.
The restructuring aims to streamline operations and ensure compliance with Reserve Bank of India (RBI) guidelines for fintechs.
Remote e-voting period is set from June 03, 2026, to July 02, 2026, with results to be declared within two working days.
The LSP business transfer includes all tangible/intangible assets, licenses, personnel, and contracts on an 'as is where is' basis.
👀 What to Watch
Investors should view this as a strategic move to ring-fence the lending business and formalize the payment aggregator vertical, which could improve regulatory clarity. Monitor the completion of the slump sale and its impact on the consolidated financial structure.
Bigbloc Construction Q4 FY26: Revenue Grows 35% to ₹87 Cr; Reports Net Loss of ₹1 Cr
Bigbloc Construction reported a robust 35% YoY revenue growth in Q4 FY26 to ₹87 crore, supported by a 40% increase in sales volumes. However, the company faced severe margin compression, with full-year EBITDA margins falling to 6.21% from 13% in FY25 due to elevated input costs and pricing pressure. Despite the top-line growth, the company posted a net loss of ₹1 crore for the quarter and ₹9 crore for the full year FY26. Management is targeting 10-20% volume growth in FY27, banking on high-margin AAC wall panels and construction chemicals to drive recovery.
Key Highlights
Sales volume for Q4 FY26 surged 40% YoY to 2,45,870 cubic meters, with full-year volume up 37%.
EBITDA margins for FY26 dropped to 6.21% from 13% in FY25, primarily due to a 5-6% drop in realizations and higher operating costs.
The company reported a net loss of ₹9 crore for FY26 on a total revenue of ₹283 crore.
New high-margin segments like AAC wall panels (30-45% EBITDA) and construction chemicals (25-30% EBITDA) are expected to contribute significantly to future revenue.
Bigbloc has accumulated 150,000 tons of carbon credits valued at $2-$3 per ton, which are expected to be monetized soon.
👀 What to Watch
Investors should closely monitor the company's ability to improve capacity utilization and pass on rising input costs to customers. While volume growth is strong, the transition back to profitability depends on the successful scaling of the high-margin AAC panel and construction chemical divisions.
Biocon Reduces Net Debt/EBITDA to 2.7x; Integrates Biosimilars for $200B Market Opportunity
Biocon has successfully integrated the Viatris biosimilar acquisition and is consolidating its business structure, now holding 99.2% of Biocon Biologics. The company significantly improved its financial health, reducing Net Debt/EBITDA from 4.3x in FY23 to 2.7x in FY26 through a ₹4,500 Cr QIP and $1.2B refinancing. With FY26 revenues at $1,924M and a portfolio of 30+ biosimilars, the company is transitioning from a heavy investment phase to a growth-focused integrated biopharma entity. Major CapEx is largely complete, and the company expects ₹300 Cr in annual interest savings from its recent debt restructuring.
Key Highlights
Reduced Net Debt/EBITDA from 4.3x (FY23) to 2.7x (FY26) through systemic debt reduction and robust EBITDA growth.
Raised ₹4,500 Cr via QIP to redeem structured instruments, resulting in projected annual interest savings of ₹300 Cr.
Consolidated Biocon Biologics ownership to 99.2%, with board approval to acquire the remaining 0.8% for full control.
Reported FY26 revenues of $1,924M, with Biosimilars contributing 60% and CRDMO services contributing 22%.
Pipeline includes 30+ biosimilars and 3 GLP-1s targeting a total addressable market of over $200B.
👀 What to Watch
Investors should view the successful deleveraging and business consolidation as a significant de-risking event. Focus should now shift to the commercial execution of the biosimilar pipeline and the margin expansion expected from reduced interest costs.
Ambica Agarbathies FY26 PAT Jumps to ₹3.45 Cr; Board Approves ₹2.04 Cr Preferential Issue
Ambica Agarbathies reported a strong recovery in profitability for the fiscal year ended March 31, 2026, with Net Profit (PAT) rising to ₹344.74 Lakhs from ₹48.86 Lakhs in the previous year. Total income for FY26 grew to ₹14,954.02 Lakhs, driven primarily by the Agarbathies division which contributed ₹11,583.75 Lakhs. The Board also approved a preferential allotment of 8,48,600 equity shares to the promoter group at ₹24 per share (including a ₹14 premium) to raise approximately ₹2.04 Crores. An Extra Ordinary General Meeting (EGM) is scheduled for June 30, 2026, to obtain shareholder approval for this fundraise.
Key Highlights
Annual Net Profit (PAT) surged significantly to ₹344.74 Lakhs in FY26 compared to ₹48.86 Lakhs in FY25.
Total Income for the full year increased by 16% year-on-year to ₹14,954.02 Lakhs.
Board approved a preferential issue of 8,48,600 equity shares to four promoter group members at ₹24 per share.
The Agarbathies division remains the core business, generating ₹11,583.75 Lakhs in revenue for the year.
Q4 FY26 showed a turnaround with a PAT of ₹81.59 Lakhs versus a loss of ₹193.53 Lakhs in the same quarter last year.
👀 What to Watch
Investors should view the sharp increase in net profit and the promoter's capital infusion as positive signals of operational recovery and management confidence. Monitor the upcoming EGM on June 30 for the formal approval of the preferential allotment.
Ambica Agarbathies FY26 Net Profit Surges to ₹3.45 Cr; Board Approves ₹2.04 Cr Preferential Issue
Ambica Agarbathies reported a significant turnaround in FY26, with Net Profit rising to ₹3.45 Cr from just ₹0.49 Cr in FY25. Total Income grew by 16% YoY to ₹149.54 Cr, primarily driven by the Agarbathies division which contributed ₹115.84 Cr. The Board also approved a preferential allotment of 8.48 lakh equity shares to the promoter group at ₹24 per share, aiming to raise approximately ₹2.04 Cr. Despite the profit growth, the Hotel division remains a laggard, reporting a loss of ₹1.08 Cr for the year.
Key Highlights
Annual Net Profit jumped to ₹344.74 Lakhs in FY26 compared to ₹48.86 Lakhs in the previous fiscal year.
Total Income for the year ended March 31, 2026, stood at ₹149.54 Cr, up from ₹128.92 Cr in FY25.
Preferential issue of 8,48,600 equity shares approved at ₹24 per share (including ₹14 premium) to four promoter group members.
Agarbathies segment remains the primary profit driver with a segment result of ₹6.11 Cr, while the Hotel segment posted a loss of ₹1.08 Cr.
Non-current borrowings increased to ₹68.28 Cr as of March 31, 2026, compared to ₹59.77 Cr in the previous year.
👀 What to Watch
Investors should view the sharp recovery in PAT and promoter capital infusion as positive signs of confidence. However, caution is advised regarding the persistent losses in the hotel segment and the company's rising debt levels.
Panacea Biotec FY26: Consolidated Revenue up 14%, Net Loss narrows to ₹7.16 Cr
Panacea Biotec reported a 14% increase in consolidated total income to ₹656.67 crore for FY26, while the consolidated net loss narrowed slightly to ₹7.16 crore from ₹8.72 crore in FY25. However, standalone performance was weaker, with the net loss widening significantly to ₹29.88 crore from ₹15.23 crore in the previous year. Due to persistent losses, the company has skipped dividend payments for the fiscal year and appointed Mr. Rajinder Singh Manku as an Independent Director.
Key Highlights
Consolidated total income rose 13.3% YoY to ₹65,667 Lakh in FY26.
Consolidated net loss narrowed to ₹716 Lakh from ₹872 Lakh in FY25.
Standalone net loss widened to ₹2,988 Lakh compared to ₹1,523 Lakh in the previous year despite revenue growth.
The Board decided to pass over dividends for FY26 on account of losses.
Mr. Rajinder Singh Manku appointed as Independent Director for a 5-year term effective July 1, 2026.
👀 What to Watch
Investors should exercise caution as the company continues to report losses at both standalone and consolidated levels. Monitor if the double-digit revenue growth can eventually lead to a turnaround in bottom-line profitability.
Panacea Biotec FY26 Consolidated Loss Narrows to ₹7.16 Cr; Revenue Up 13% to ₹640 Cr
Panacea Biotec Limited reported a consolidated total income of ₹65,667 lakh for the financial year ended March 31, 2026, marking a 13.3% growth compared to ₹57,975 lakh in FY25. The consolidated net loss narrowed to ₹716 lakh from ₹872 lakh in the previous year, aided by exceptional items of ₹1,950 lakh. However, standalone performance remained under pressure with the net loss widening significantly to ₹2,988 lakh from ₹1,523 lakh. Consequently, the company has skipped dividend payments for the year.
Key Highlights
Consolidated revenue from operations increased by 14.4% YoY to ₹63,977 lakh in FY26.
Consolidated net loss for the year narrowed to ₹716 lakh compared to a loss of ₹872 lakh in FY25.
Standalone net loss widened by 96% to ₹2,988 lakh for FY26, up from ₹1,523 lakh in the previous year.
The Board of Directors recommended passing over dividends for both equity and preference shares due to losses.
Mr. Rajinder Singh Manku was appointed as an Additional Independent Director for a 5-year term starting July 1, 2026.
👀 What to Watch
Investors should exercise caution as the widening standalone losses and lack of dividends reflect ongoing operational challenges despite the marginal improvement in consolidated bottom-line figures.
SBI Cards Appoints Saurav Ghosh as COO for 2 Years; Ashutosh Sharma to Step Down
SBI Cards and Payment Services has announced the appointment of Mr. Saurav Ghosh as the new Chief Operating Officer (COO) for a fixed term of 2 years, effective June 21, 2026. He will succeed the outgoing COO, Mr. Ashutosh Kumar Sharma, whose term concludes at the close of business hours on June 20, 2026. Mr. Ghosh brings over 24 years of extensive experience in banking operations, credit management, and digital transformation to the role. The transition was approved by the Board of Directors following recommendations from the Nomination and Remuneration Committee.
Key Highlights
Mr. Saurav Ghosh appointed as Chief Operating Officer for a 2-year term starting June 21, 2026.
Outgoing COO Mr. Ashutosh Kumar Sharma to demit office on June 20, 2026, following the completion of his tenure.
New appointee Mr. Ghosh has over 24 years of experience across banking operations, HR, and regulatory compliance.
The Board meeting approving the change commenced at 4:00 p.m. and concluded at 5:52 p.m. on May 30, 2026.
👀 What to Watch
Investors should view this as a planned leadership transition and monitor if the new COO introduces any significant shifts in operational efficiency or digital strategy.
SBI Cards Appoints Saurav Ghosh as COO for 2 Years; Ashutosh Sharma to Step Down
SBI Cards and Payment Services Limited has announced a transition in its senior leadership following a board meeting on May 30, 2026. Mr. Saurav Ghosh has been appointed as the Chief Operating Officer (COO) for a 2-year term effective June 21, 2026. He replaces the outgoing COO, Mr. Ashutosh Kumar Sharma, who will demit office on June 20, 2026, upon the completion of his tenure. Mr. Ghosh brings over 24 years of experience in banking operations, credit management, and digital transformation to the role.
Key Highlights
Mr. Saurav Ghosh appointed as Chief Operating Officer for a fixed term of 2 years.
The appointment is effective from June 21, 2026, following NRC recommendation.
Current COO Mr. Ashutosh Kumar Sharma to exit on June 20, 2026, after completing his term.
Incoming COO Saurav Ghosh has 24+ years of experience across banking operations and regulatory compliance.
The board meeting concluded at 5:52 p.m. on May 30, 2026.
👀 What to Watch
Investors should view this as a routine leadership succession; monitor if the new COO's digital transformation expertise leads to improved operational efficiencies.
Biofil Chemicals FY26 Net Profit Jumps 400% to ₹2.78 Cr Driven by Other Income
Biofil Chemicals reported a significant 399% increase in annual net profit to ₹278.60 lakhs for FY26, compared to ₹55.78 lakhs in FY25. This surge was primarily driven by a massive spike in 'Other Income' which reached ₹308.23 lakhs, while core revenue from operations actually declined by 15% YoY to ₹2839.52 lakhs. For the fourth quarter (Q4 FY26), the company recorded a net profit of ₹21.22 lakhs on revenue of ₹756.56 lakhs. Despite the revenue drop, the company managed to reduce its total annual expenses by 15% to ₹2802.79 lakhs.
Key Highlights
Annual net profit surged to ₹278.60 lakhs in FY26 from ₹55.78 lakhs in FY25.
Other Income spiked to ₹308.23 lakhs in FY26, up from just ₹30.52 lakhs in the previous year.
Revenue from operations for FY26 decreased by 15% to ₹2839.52 lakhs compared to ₹3340.22 lakhs in FY25.
Total annual expenses were reduced to ₹2802.79 lakhs from ₹3297.13 lakhs YoY.
Q4 FY26 revenue stood at ₹756.56 lakhs with a net profit of ₹21.22 lakhs.
👀 What to Watch
Investors should be cautious as the profit growth is largely attributed to non-operational 'Other Income' rather than core business growth. It is advisable to investigate the source of this other income and monitor if the company can reverse the declining trend in its core operational revenue.
Concord Biotech FY26 PAT drops 30% to ₹259 Cr amid global headwinds and procurement delays
Concord Biotech reported a challenging FY26 with consolidated revenue declining 12% YoY to ₹1,054.9 crore and PAT falling 30% to ₹259.2 crore. EBITDA margins saw significant compression, dropping to 34.8% from 42.2% in the previous year, primarily due to geopolitical tensions in the Middle East and a shift in US procurement patterns from bulk to staggered orders. Despite the financial dip, the company successfully commercialized its injectable facility and established a US subsidiary, Stellon Biotech, to strengthen its global footprint.
Key Highlights
Consolidated Revenue for FY26 decreased by 12% YoY to ₹1,054.9 crore compared to ₹1,200.1 crore in FY25.
Full-year EBITDA margin contracted by 736 bps to 34.8%, while Q4FY26 margin stood at 36.4%.
Net Profit (PAT) for the year declined by 30% YoY to ₹259.2 crore from ₹371.6 crore.
API segment remains the primary driver contributing 79% of total revenue, with formulations at 21%.
Management identified specific headwinds including a 3-month delay in EU regulatory confirmations and US Veterans Affairs tender delays.
👀 What to Watch
Investors should exercise caution due to the significant margin contraction and revenue decline, though management's optimism for an FY27 recovery backed by new injectable and soft gel facilities warrants a 'watch' for signs of turnaround in the next two quarters.
